Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial

Walma, M. S., Rombouts, S. J., Brada, L. J. H., Borel Rinkes, I. H., Bosscha, K., Bruijnen, R. C., Busch, O. R., Creemers, G. J., Daams, F., van Dam, R. M., van Delden, O. M., Festen, S., Ghorbani, P., de Groot, D. J., de Groot, J. W. B., Haj Mohammad, N., van Hillegersberg, R., de Hingh, I. H., D’Hondt, M., Kerver, E. D., van Leeuwen, M. S., Liem, M. S., van Lienden, K. P., Los, M., de Meijer, V. E., Meijerink, M. R., Mekenkamp, L. J., Nio, C. Y., Oulad Abdennabi, I., Pando, E., Patijn, G. A., Polée, M. B., Pruijt, J. F., Roeyen, G., Ropela, J. A., Stommel, M. W. J., de Vos-Geelen, J., de Vries, J. J., van der Waal, E. M., Wessels, F. J., Wilmink, J. W., van Santvoort, H. C., Besselink, M. G., Molenaar, I. Q.

Approximately 80% of patients with locally advanced pancreatic cancer (LAPC) are treated with chemotherapy, of whom approximately 10% undergo a resection. Cohort studies investigating local tumor ablation with radiofrequency ablation (RFA) have reported a promising overall survival of 26-34 months when given in a multimodal setting. However, randomized controlled trials (RCTs) investigating the effect of RFA in combination with chemotherapy in patients with LAPC are lacking. The "Pancreatic Locally Advanced Unresectable Cancer Ablation" (PELICAN) trial is an international multicenter superiority RCT, initiated by the Dutch Pancreatic Cancer Group (DPCG). All patients with LAPC according to DPCG criteria, who start with FOLFIRINOX or (nab-paclitaxel/)gemcitabine, are screened for eligibility. Restaging is performed after completion of four cycles of FOLFIRINOX or two cycles of (nab-paclitaxel/)gemcitabine (i.e., 2 months of treatment), and the results are assessed within a nationwide online expert panel. Eligible patients with RECIST stable disease or objective response, in whom resection is not feasible, are randomized to RFA followed by chemotherapy or chemotherapy alone. In total, 228 patients will be included in 16 centers in The Netherlands and four other European centers. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, RECIST response, CA 19.9 and CEA response, toxicity, quality of life, pain, costs, and immunomodulatory effects of RFA. The PELICAN RCT aims to assess whether the combination of chemotherapy and RFA improves the overall survival when compared to chemotherapy alone, in patients with LAPC with no progression of disease following 2 months of systemic treatment. Dutch Trial Registry NL4997 . Registered on December 29, 2015. ClinicalTrials.gov NCT03690323 . Retrospectively registered on October 1, 2018.